Form 4: Maravai LifeSciences Holdings Officer Rebecca Buzzeo Reports Acquisition of Class A Common Stock

Sentiment:

SEC Form 4 Filing


Rebecca Buzzeo, Chief Commercial Officer of Maravai LifeSciences Holdings, reports acquiring 295,858 shares of Class A Common Stock through restricted stock units.

Summary

  • This Form 4 filing reports a change in beneficial ownership of Maravai LifeSciences Holdings, Inc. (MRVI) stock by Rebecca Buzzeo, the Chief Commercial Officer.
  • On March 17, 2025, Buzzeo acquired 295,858 shares of Class A Common Stock.
  • These shares were acquired through restricted stock units (RSUs) awarded under the company's 2020 Omnibus Incentive Plan.
  • Each RSU represents the right to receive one share of Class A Common Stock upon vesting.
  • The RSUs will vest in 1/3rd increments on March 15, 2026, March 15, 2027, and March 15, 2028, contingent upon Buzzeo's continued employment with the Issuer.
  • Following the transaction, Buzzeo directly owns 606,791 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and aligns executive interests with shareholder value. There are no red flags or negative implications.

Positives

  • The grant of RSUs to a key officer like the Chief Commercial Officer aligns her interests with the long-term success of the company.
  • The vesting schedule encourages continued employment and dedication to the company's goals.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

This type of filing is standard for publicly traded companies and reflects the compensation practices of awarding equity to key executives.

Stakeholder Impact

  • Shareholders may view the RSU grant as a positive sign, aligning management's interests with the company's long-term performance.
  • Employees may see this as a positive sign of the company investing in its leadership.

Key Dates

DateDescription
03/17/2025Date of transaction: Rebecca Buzzeo acquired Class A Common Stock.
03/19/2025Date of signature on the Form 4 filing.
03/15/2026First vesting date for 1/3rd of the RSUs.
03/15/2027Second vesting date for 1/3rd of the RSUs.
03/15/2028Final vesting date for 1/3rd of the RSUs.

Keywords

Form 4, Beneficial Ownership, Maravai LifeSciences, MRVI, Rebecca Buzzeo, Restricted Stock Units, RSUs, Class A Common Stock, Officer, Chief Commercial Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.